There have been number of high profile lawsuits alleging illegal marketing practices launched by the Department of Justice against pharmaceutical companies in recent years. Previous fines for illegal marketing practices (among other things) included $2.3 billion settlements from Pfizer and $1.4 billion from Eli Lilly. Now the Department of Justice and other government agencies are set to obtain $3 billion from Glaxo. I spoke to Ralph Hall, an attorney and Professor of Practice at the University of Minnesota Law School, and asked him how the case would affect the ongoing battle over industry marketing practices.
"The marketing issues" he explained, "include concerns over off-label promotion and company interactions with physicians." Under existing FDA regulations, companies are prohibited from communicating any information about potential off-label uses to physicians, even if the information has been previously published in peer-reviewed journals. Glaxo's settlement, however is unlikelty to settle the issue: "The FDA's legal basis for prohibiting truthful off-label promotion is currently being challenged in the 2nd Circuit in U.S. v Caronia. This case - a 1st Amendment challenge - may well settle the question whether truthful off-label promotion is considered protected speech."
Given the rapid advance of medical innovation, and the importance of off-label treatments for many diseases, from cancer to Lupus, a strong case can be made for allowing companies to present to physicians (who are, after all, experts) truthful evidence from peer-reviewed journals. The FDA might argue this would discourage companies form seeking additional label indications for off-label uses, but the real disincentive is the enormous time and cost associated with seeking FDA approval for new indications, which can cost billions and take over a decade. Some compromise would seem to be in order - perhaps with a qualification that the evidence hasn't been reviewed by the FDA, and may be disproved by additional research. Still, physicians already know this - and should be trusted to make their own educated decisions with all the evidence available to them.
Glaxo's $3 billion settlement and off-label prescribing
Tweet
No TrackBacks
TrackBack URL: http://www.medicalprogresstoday.com/cgi-bin/mt/mt-tb.cgi/124
|
keep in touch |
Our Research
Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials
by Avik Roy, April 2012
Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research
by Tomas J. Philipson, Eric Sun, June 2011
How Conflict-of-Interest Rules Endanger Medical Progress and Cures
by Richard A. Epstein, October 2010
Cost of Caution: The Impact on Patients of Delayed Drug Approvals
by Tomas J. Philipson, Eric Sun, June 2010
In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation
by James R. Copland, Paul Howard, March 2009
MORE REPORTS >>
by Avik Roy, April 2012
Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research
by Tomas J. Philipson, Eric Sun, June 2011
How Conflict-of-Interest Rules Endanger Medical Progress and Cures
by Richard A. Epstein, October 2010
Cost of Caution: The Impact on Patients of Delayed Drug Approvals
by Tomas J. Philipson, Eric Sun, June 2010
In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation
by James R. Copland, Paul Howard, March 2009
MORE REPORTS >>
Blogroll
American Council on Science and Health
in the Pipeline
Drugwonks
Pharmalot
Reason – Peter Suderman
WSJ Health Blog
The Hill’s Healthwatch
Forbes ScienceBiz
The Apothecary
EyeOnFDA
KevinMD
Marginal Revolution
Megan McArdle
LifeSci VC
Critical Condition
EconLog
In Vivo Blog
PharmaGossip
Pharma Strategy Blog
Drug Discovery Opinion



Leave a comment